Company intelligence / Profile preview

Antion Biosciences

Ownership: Private
Development stage: Preclinical

Overview

Antion has demonstrated preclinical proof-of-concept for its allogeneic anti-CD7 CAR T-cell product (“miCAR7”), showing highly effective tumor control in animal models. The company’s technology enables simultaneous modulation of multiple genes from a single construct, resulting in high purity (>99%) engineered cells with enhanced safety profiles. Additional preclinical data support the development of allogeneic CAR-T solutions for HIV and other indications.

Therapeutic areas: OncologyImmunologyNeurologyInfectious Diseases
Modalities: Allogeneic cell therapies (CAR T-cells)Gene-modified cell therapiesNucleic acid drugs
Industry: Biotech

Drug pipeline

2 assets

miCAR19

Preclinical

1 more asset in the full pipeline.

Partnerships

Collaboration with Allogene Therapeutics to validate platform technology; milestone achievements reported March 2024.

Beyond the preview

Go deeper on Antion Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antion Biosciences.